Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Zalcitabine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.62 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.62 |
| ▸ | ALB | P02768 | 3/20 | 0.62 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.62 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.62 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.62 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.62 |
| ▸ | ABL1 | P00519 | 1/20 | 0.58 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.58 |
| ▸ | THRB | P10828 | 1/20 | 0.54 |
| ▸ | MTOR | P42345 | 1/20 | 0.54 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.54 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.54 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.54 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.51 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.51 |
| ▸ | POLG | P54098 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Zalcitabine SCHEMBL21100417 | 1.00 | LMNA (0.62) | LMNAPDE3AALBCACNA1FMAPT | |
| Zalcitabine SCHEMBL10380711 | 1.00 | LMNA (0.62) | LMNAPDE3AALBCACNA1FMAPT | |
| Zalcitabine SCHEMBL598496 | 1.00 | LMNA (0.62) | LMNAPDE3AALBCACNA1FMAPT | |
| Zalcitabine SCHEMBL9194365 | 1.00 | LMNA (0.62) | LMNAPDE3AALBCACNA1FMAPT | |
| Zalcitabine SCHEMBL3598 | 1.00 | LMNA (0.62) | LMNAPDE3AALBCACNA1FMAPT | |
| Zalcitabine SCHEMBL12149465 | 1.00 | LMNA (0.62) | LMNAPDE3AALBCACNA1FMAPT | |
| Zalcitabine SCHEMBL8094882 | 1.00 | LMNA (0.62) | LMNAPDE3AALBCACNA1FMAPT | |
| Zalcitabine SCHEMBL3235525 | 1.00 | LMNA (0.62) | LMNAPDE3AALBCACNA1FMAPT | |
| Zalcitabine SCHEMBL27555151 | 0.99 | LMNA (0.60) | LMNAPDE3AALBCACNA1FMAPT | |
| Zalcitabine SCHEMBL29277683 | 0.99 | LMNA (0.60) | LMNAPDE3AALBCACNA1FMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010112033-A2 | METHOD FOR ESTIMATING THE RISK OF HAVING OR DEVELOPING MULTIPLE SCLEROSIS USING SEQUENCE POLYMORPHISMS IN A SPECIFIC REGION OF CHROMOSOME X | ØSTJYSK INNOVATION A/S (DK) | 2010-10-07 | — | — | WO | disclosed |